Pfizer · NSE: PFIZER · BSE: 500680
Q4 FY20 results · Jan–Mar 2020
Pfizer reported revenue from operations of ₹502.01 crore (down 6.3% from Q4 FY19) and net profit of ₹103.01 crore (down 5.9% from Q4 FY19) for Q4 FY20 (Jan–Mar 2020), on a standalone basis.
| Item | Q4 FY20 | Q4 FY19 | YoY | Q3 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 502.01 | 535.66 | −6.3% | 538.18 | −6.7% |
| Other income | 45.22 | 35.45 | +27.6% | 58.22 | −22.3% |
| Total income | 547.23 | 571.11 | −4.2% | 596.40 | −8.2% |
| Profit before tax | 121.90 | 168.22 | −27.5% | 164.50 | −25.9% |
| Net profit for the period | 103.01 | 109.47 | −5.9% | 139.06 | −25.9% |
| EPS, basic (₹) | 22.52 | 23.93 | −5.9% | 30.40 | −25.9% |
| Net margin (%) | 20.5 | 20.4 | 25.8 |
Standalone
- Filed with BSE
- 15 Jun 2020, 18:04 IST
- Board meeting
- 15 Jun 2020
- Period
- 01 Jan 2020 to 31 Mar 2020
- Review status
- Audited
- Source
- XBRL filing on BSE